There is an urgent need for a water-soluble derivative of astragaloside IV for drug R&D. In the present study, a remarkably simple method for the preparation of such a water-soluble derivative of astragaloside IV has been developed. This protocol involves oxidative 2,2,6,6-tetramethylpiperidine-1-oxyl free radical (TEMPO)-mediated transformation of astragaloside IV to its carboxylic acid derivative, which is a new compound named astragalosidic acid. The structure of astragalosidic acid was elucidated by means of spectroscopic analysis. Its cardioprotective activity was investigated using an in vitro model of cardiomyocyte damage induced by hypoxia/reoxygenation in H9c2 cells. The oxidative TEMPO-mediated transformation proposed in the present study could be applied to other natural saponins, offering an effective and convenient way to develop a new compound with greatly improved structure-based druggability.
Introduction
Astragali Radix is a well-known herbal drug in traditional Chinese medicine which has been used to treat numerous diseases for hundreds of years.
To date, more than 200 kinds of traditional Chinese medicine patent prescription containing Astragali Radix extract have been approved by the China Food and Drug Administration. Astragaloside IV (3-O-β-D-xylopyranosyl-6-O-β-D-glucopyranosyl-cycloastragenol), an active substance of Astragali Radix, has been used as a chemical marker for quality control of Astragali Radix and its preparation in the Chinese Pharmacopoeia [1] . Despite its well-documented pharmacological effects [2, 3] , the druggability of astragaloside IV, related to its characteristics of solubility, dissolution, and gastrointestinal permeability, has always attracted research interest. Poor water solubility and poor dissolution in the gastrointestinal fluids of astragaloside IV is a limiting factor to in vivo bioavailability [4, 5] . Therefore, there is an immediate need for a water-soluble derivative of astragaloside IV using a low-cost preparation method in drug R&D.
Due to the structural complexity of astragaloside IV (it has a number of potential chemical reaction sites), so far there has been no feasible reported method for preparing a water-soluble derivative. Salt formation is the most common and effective way to improve druggability, increasing solubility and dissolution rates of the pharmaceutical compound [6] . Among a variety of chemical approaches, 2,2,6,6-tetramethylpiperidine-1-oxyl free radical (TEMPO) is a classic nitroxide radical, which can selectively oxidize the primary alcohol to carbohydrate [7] [8] [9] . In this work, a new water-soluble derivative of astragaloside IV, compound 1, was prepared by remarkably simple TEMPO-mediated oxidation, offering a promising option for natural drug research. Herein, we describe the preparation, structural elucidation, and in vitro cardioprotective activity of this new compound.
Results and Discussion

Preparation of Compound 1
A total of 200 mg astragaloside IV was added in to 200 mL water containing 100 mg NaBr, 40 mg TEMPO, and 1 mL NaClO. The reaction mixture was stirred rapidly in open air at 20 ± 0.5 • C and monitored by thin-layer chromatography (TLC) until no starting material remained. After reacting for 2 h, the mixture was filtered, and the oxidation was terminated by adjusting the pH to 2. The reaction mixture was concentrated to about 10 mL, filtered, and then washed by 2 mL acid water to obtain compound 1 (172 mg) with a yield of 84.5%. The reaction pathway is depicted in Figure 1 . 
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Investigation of Cardioprotective Activity In Vitro
To examine the potential bioactivity of compound 1, we employed a well-established in vitro cardiomyocyte injury model that was induced by hypoxia/reoxygenation (H/R). As shown in Figure 3 , H/R induction significantly reduced the cell viability and mitochondrial viability in H9c2 cells compared with the normoxia group (p < 0.001, p < 0.001, respectively). Compound 1 at 2.5, 5 and 10 mg/L significantly increased cell viability and mitochondrial viability in a dose-dependent manner, suggesting its protective effect against the H/R-induced cardiomyocyte death. For the myocardial injury detection, compound 1 was investigated by cytosolic creatine kinase (CK) and lactate dehydrogenase (LDH) activity in H9c2 cells. H/R significantly increased LDH release and CK content compared with the normoxia group (p < 0.001, p < 0.001, respectively). Our results in Figure 4 indicated that compound 1 significantly inhibited the rise of myocardial enzyme markers induced by H/R in a dose-dependent manner.
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Materials and Methods
Apparatus and Materials
Astragaloside IV was prepared in-house from Astragali Radix with structure characterization by multiple spectroscopic analysis (UV, IR, HR-ESI-MS, 1 H-NMR, and 13 C-NMR) and comparison with the literature. Bruker AVANCE 600 NMR (Bruker, Zurich, Switzerland) and MicrOTOF QII HR-MS (Bruker Daltonik, Germany) were applied for structure elucidation. TLC plates were prepared in-house with silica gel G and CMC-Na. Milli-Q water (Millipore Corp., Bedford, MA, USA) was used throughout the work. Other chemicals and solvents were of analytical reagent grade. Fetal bovine serum was purchased from Sigma-Aldrich (St. Louis, MO, USA). The rat H9c2 cardiomyocyte cell line was purchased from the American Type Culture Collection (CRL1446, ATCC, Manassas, VA, USA). Dulbecco's Modified Eagle Medium (Gibco, Langley, OK, USA) and Billups-Rotenberg modular incubator chamber (Billups-Rotenberg, Del Mar, CA, USA) were used for the cells grown. The UV absorbance was determined using the Infinite M200pro microplate reader (Tecan, Mannedorf, Switzerland). The fluorescence was also detected using the Infinite M200pro microplate reader. Mitochondrial viability was evaluated by the mitochondrial viability assay kit (Abcam, Cambridge, UK) according to the manual. Activities of CK and LDH were detected by the commercial assay kits (Biovision, Milpitas, CA, USA) according to the manufacturer's recommendations. 
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Acid Hydrolysis of Compound 1
Compound 1 (10 mg) was heated with 1.5 M HCl-CH 3 OH (20 mL) under reflux for 8 h. The reaction mixture was subjected to silica gel TLC, together with the standard samples, using CHCl 3 -CH 3 OH-H 2 O-CH 3 COOH (5:6:1:1) as the developing solvent and using O-phthalic acid-aniline as the detection reagent. Xylose (R f 0.86), and glycuronic acid (R f 0.23) were detected. Cells were grown in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% v/v penicillin/streptomycin at 37 • C in a 5% CO 2 humidified atmosphere. Compound 1 was dissolved in culture medium to the indicated final concentrations (2.5, 5 and 10 mg/L) before treatment. Cells were exposed to compound 1 for 30 min, and then subjected to H/R as described by us previously [12] . Briefly, medium was replaced with Krebs-Ringer Bicarbonate (KRB) buffer (115 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 24 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 10 mM Hepes and 0.01% bovine serum albumin), placed in a Billups-Rotenberg modular incubator chamber saturated with 99.99% nitrogen. After 3 h of hypoxia, KRB buffer was replaced with DMEM with 10% FBS under 21% O 2 for 3 h of reoxygenation.
Bioactivity Evaluation
Cell and Mitochondrial Viability Assay
After treatments, cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The absorbance was detected at 570/650 nm on an Infinite M200pro microplate reader. Mitochondrial viability was evaluated by the mitochondrial viability assay kit according to the manual. Fluorescence was detected at 590 nm with an excitation wavelength of 550 nm by the Infinite M200pro microplate reader.
Creatine Kinase and Lactate Dehydrogenase Activity Detection
The activity of CK and LDH were detected by the commercial assay kits according to the manufacturer's recommendations.
Conclusions
In conclusion, the present study reported the preparation, structure elucidation, and cardioprotective activity of astragalosidic acid, a new carboxylic acid derivative of astragaloside IV oxidized by TEMPO-mediated transformation. The results showed that astragaloside acid was a new compound with great potential for new drug R&D. This is the first report of selective oxidation of saponin through the primary alcohols on its sugar chains. Furthermore, the methodology proposed in the present study could be applied to other natural saponins, offering an effective and convenient way to develop a new compound with greatly improved structure-based druggability. 
